I was like, oh my God, what happens if it doesn’t work’? Young people living with HIV, clinical trial participation and the truth economy
11 Sep, 2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T Published: BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148)
Read MoreI am scared of getting caught up in my lie’: challenges to self-reported adherence for young people living with HIV
18 Jul, 2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams. Published in: accepted for presentation at AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)
Read MoreYoung people, clinical trials and ‘the HIV experience’: What can similarities across time and place tell us about growing up with HIV?
18 Jul, 2015
Authors: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team. Published in: 3rd International ASSHH Conference, Stellenbosch,…
Read More“But it’s my story”: exploring the experience and effect of telling children how they have acquired HIV
18 Jul, 2015
Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S, Rhodes T and the BREATHER Trial Team. Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9…
Read MoreOnce vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.
19 Apr, 2015
Authors: Paediatric European Network for Treatment of AIDS (PENTA). Published in: AIDS 2015. 29(18):2447-2457 Objective To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in…
Read MoreART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI
23 Feb, 2015
Authors: Karina M. Butler on behalf of the BREATHER trial team Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015. Abstract For HIV-1 infected young people (YP) facing lifelong ART,…
Read MoreLong-term consequences of planned treatment interruption in HIV-1-infected children.
18 Feb, 2015
Authors: Freguja R, De Rossi A, Paulson H, Klein N, Del Bianco P, Compagnucci A, Saidi Y, Giaquinto C, Harper L, Gibb D, on behalf of the PENTA Steering Committee…
Read MoreHIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds
01 Jan, 2015
Authors: Harrison L, Melvin A, Fiscus S, et al; PENPACT-1 (PENTA 9PACTG 390) Study Team. Published in: J Acquir Immune Defic Syndr. 2015;70(1):42-53 Background The PENPACT-1 trial compared virologic thresholds to determine when…
Read MoreUsing CD4 Percentage and Age to Optimize Pediatric Antiretroviral Therapy Initiation
18 Apr, 2014
Authors: Yin D., Warshaw M., Miller W., Castro H., Fiscus S., Harper L., Harrison L., Klein N., Lewis J., Melvin A., Tudor-Williams G., McKinney R. Published in: Pediatrics, 2014;134(4):e1104-16 Background Quantifying…
Read MorePharmacokinetics of Pediatric Lopinavir/Ritonavir Tablets in Children When Administered Twice Daily According to FDA weight bands.
10 Apr, 2014
Authors: Bastiaans DE, Forcat S, Lyall H, et al. Published in: Pediatr Infect Dis J. 2014;33(3):301-305 Background Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA)…
Read MoreHIV-1 resistance after randomized virologic switch at 1,000 or 30,000 c/ml in children.
18 Mar, 2014
Authors: Harrison L, Gibb DM, Fiscus S, Saïdi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, Melvin A, Tudor-Williams G and the PENPACT 1 (PENTA 9/PACTG 390) Study Team.…
Read MoreThe Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection.
23 Oct, 2013
Authors: Klein N, Sefe D, Mosconi I, et al; on Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team Published in: PLoS One. 2013;8(10):e76582. Objective…
Read MorePharmacokinetics of paediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
19 May, 2013
Authors: D Bastiaans, S Forcat, H Lyall, T Cressey, S Chalermpantmetagul, Y Saïdi, C Koenigs, D Nayagam, A Compagnucci, S Montero, L Harper, C Giaquinto, E Colbers, D Burger. Published…
Read MoreOutcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions in the PENTA 11 Study
18 Feb, 2013
Authors: Bunupuradah T, Duong T, Compagnucci A, et al; on behalf of the PENTA 11 Extension Study Group Published in: AIDS. 2013;27(4):579-89 Background Excess risks for death/opportunistic disease in adults randomized…
Read MoreAdherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children
17 Jan, 2013
Here have been no paediatric randomised trials describing the effect of planned treatment interruptions (PTIs) of antiretroviral therapy (ART) on adherence, or evaluating acceptability of such a strategy. In PENTA…
Read MorePharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands.
19 Jul, 2012
Authors: Bastiaans DET, Forcat S, Lyall HEG, Cressey TR, Chalermpantmetagul S, Saïdi Y, Noguera T, Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers EP, Burger DM. Published in: 4th…
Read MoreNeurocognitive and Quality of Life Outcomes in Children after Planned Treatment Interruptions: the randomized PENTA 11 trial.
08 May, 2012
Authors: Ramos J., Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee. Published in:…
Read MorePharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weightbands.
19 Apr, 2012
Authors: D Bastiaans, S. Forcat, H.E.G. Lyall, T.R. Cressey, S. Chalermpantmetagul, Y. Saïdi, H.J. Scherpbier, A. Warris, A. Compagnucci, C. Giaquinto, E.P. Colbers, D.M. Burger on behalf of PENTA KONCERT…
Read More